Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...
New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...
Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...
The National on MSN1d
Two years on, are GLP-1 drugs such as Ozempic and Mounjaro here to stay?In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback